$STTK
Shattuck Labs Inc Stock $sttk

$sttk Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000168036721000008 Filed on March 16, 2021

Income Statement

Concept	2019 Q4	2019
Revenue	$9.887M	$9.887M
YoY Change		-55.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.736M	$5.740M
YoY Change		51.85%
% of Gross Profit
Research & Development	$29.22M	$29.22M
YoY Change		17.77%
% of Gross Profit
Depreciation & Amortization	$250.0K	$500.0K
YoY Change		92.31%
% of Gross Profit
Operating Expenses	$34.95M	$34.95M
YoY Change		22.26%
Operating Profit		-$25.07M
YoY Change
Interest Expense	$1.184M	$1.180M
YoY Change		-170.66%
% of Operating Profit
Other Income/Expense, Net	-$99.00K	$1.085M
YoY Change		-401.39%
Pretax Income	-$23.98M	-$23.98M
YoY Change		224.49%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$23.98M	-$23.98M
YoY Change		224.52%
Net Earnings / Revenue	-242.56%	-242.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$629.8K	-$629.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.09M	$39.10M
YoY Change		-35.26%
Cash & Equivalents	$7.013M	$7.000M	$31.64M
Short-Term Investments	$32.07M	$32.10M
Other Short-Term Assets		$3.400M
YoY Change		-35.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$42.44M	$42.40M
YoY Change		-35.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.437M	$2.400M
YoY Change		-4.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$90.00K	$100.0K
YoY Change
Total Long-Term Assets	$2.527M	$2.600M
YoY Change		0.0%
TOTAL ASSETS
Total Short-Term Assets	$42.44M	$42.40M
Total Long-Term Assets	$2.527M	$2.600M
Total Assets	$44.97M	$45.00M
YoY Change		-34.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.051M	$3.100M
YoY Change		55.0%
Accrued Expenses		$4.000M
YoY Change		122.22%
Deferred Revenue	$12.89M
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.98M	$20.00M
YoY Change		-4.31%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$10.50M
YoY Change		12.9%
Total Long-Term Liabilities		$10.50M
YoY Change		12.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.98M	$20.00M
Total Long-Term Liabilities		$10.50M
Total Liabilities	$30.45M	$30.50M
YoY Change		0.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$35.49M
YoY Change
Common Stock	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$34.55M	$14.50M	-$11.08M
YoY Change
Total Liabilities & Shareholders Equity	$44.97M	$45.00M
YoY Change		-34.02%

Cashflow Statement

Concept	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$23.98M	-$23.98M
YoY Change		224.52%
Depreciation, Depletion And Amortization	$250.0K	$500.0K
YoY Change		92.31%
Cash From Operating Activities	-$15.11M	-$20.98M
YoY Change		203.99%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	$470.0K
YoY Change		-139.83%
Acquisitions
YoY Change
Other Investing Activities	-$710.0K	-$3.120M
YoY Change		-89.15%
Cash From Investing Activities	-$830.0K	-$3.592M
YoY Change		-88.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	-$64.00K
YoY Change		-100.18%
NET CHANGE
Cash From Operating Activities	-15.11M	-$20.98M
Cash From Investing Activities	-830.0K	-$3.592M
Cash From Financing Activities	-60.00K	-$64.00K
Net Change In Cash	-16.00M	-$24.63M
YoY Change		1366.13%
FREE CASH FLOW
Cash From Operating Activities	-$15.11M	-$20.98M
Capital Expenditures	-$120.0K	$470.0K
Free Cash Flow	-$14.99M	-$21.45M
YoY Change		274.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001680367
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:LicenseMember
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-39593
CY2020	dei	Entity Registrant Name EntityRegistrantName	Shattuck Labs, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2575858
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	1018 W. 11th Street
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78703
CY2020	dei	City Area Code CityAreaCode	919
CY2020	dei	Local Phone Number LocalPhoneNumber	864-2700
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2020	dei	Trading Symbol TradingSymbol	STTK
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Public Float EntityPublicFloat	553524346	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41775765	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157898000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7013000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	177551000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32074000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10190000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3355000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	345639000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	42442000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2437000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	349000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	90000	USD
CY2020Q4	us-gaap	Assets Assets	348988000	USD
CY2019Q4	us-gaap	Assets Assets	44969000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1754000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3051000	USD
CY2020Q4	sttk	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	7352000	USD
CY2019Q4	sttk	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	4039000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7728000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12894000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16834000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19984000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21306000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9571000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	987000	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	898000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	39127000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	30453000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41779183	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7632777	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41767431	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7600877	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	382012000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	887000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-63000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	54000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72093000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35490000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	309861000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-34548000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348988000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44969000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9934000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9887000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37483000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29218000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9382000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5736000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	46865000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	34954000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-36931000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-25067000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	549000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	1184000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-221000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-99000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-117000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	328000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1085000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-117000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	54000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36720000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23928000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.36
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.17
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15506067	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7556812	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-11081000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	461000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	54000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-34548000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	229000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1266000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	213530000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	309861000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36603000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2020	us-gaap	Depreciation Depreciation	618000	USD
CY2019	us-gaap	Depreciation Depreciation	537000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1266000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	461000	USD
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-1000	USD
CY2019	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	166000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6835000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1903000	USD
CY2020	sttk	Increase Decrease In Noncurrent Asset IncreaseDecreaseInNoncurrentAsset	326000	USD
CY2019	sttk	Increase Decrease In Noncurrent Asset IncreaseDecreaseInNoncurrentAsset	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1751000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1003000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3313000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2276000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6569000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2966000	USD
CY2020	sttk	Increase Decrease In Deferred Rent Credits IncreaseDecreaseInDeferredRentCredits	-89000	USD
CY2019	sttk	Increase Decrease In Deferred Rent Credits IncreaseDecreaseInDeferredRentCredits	41000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33659000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20975000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	727000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	470000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	37595000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	41148000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	183190000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	44270000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-146322000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3592000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	232301000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	229000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	330866000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-64000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	150885000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24631000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7013000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31644000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157898000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7013000	USD
CY2020	sttk	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	0	USD
CY2019	sttk	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	3000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	454000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the “Company”) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has two clinical-stage product candidates, SL-172154 and SL-279252, and has several compounds in preclinical development. </span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Split</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 1, 2020, the Board of Directors and the stockholders of the Company approved a 6.85-for-1 stock split of the Company’s outstanding common stock and adjusted the conversion ratio of the Company’s preferred stock accordingly. All common stock, preferred stock, and per share information has been retroactively adjusted to give effect to this forward stock split and the adjusted conversion ratios for all periods presented. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately increased and the respective per share value and exercise prices, if applicable, were proportionately decreased in accordance with the terms of the agreements governing such securities. There were no changes in the par values of the Company’s common stock and preferred stock as a result of the forward stock split.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2020, the Company completed the initial public offering ("IPO") of its common stock pursuant to a Registration Statement on Form S-1 as amended (File Nos. 333-248918 and 333-249393). The Company sold an aggregate of 13,664,704 shares of common stock (including 1,782,352 shares issued pursuant to the underwriters' option to purchase additional shares) at a public offering price of $17.00 per share. The Company received net proceeds of approximately $213.5 million, after deducting underwriting discounts and commissions and offering expenses of $18.8 million. Upon the completion of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock were converted into 20,300,253 shares of common stock.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $72.1 million as of December 31, 2020. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company’s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company’s cash and cash equivalents and short-term investments of $335.4 million as of December 31, 2020, are sufficient to fund projected operations of the Company through at least the end of 2024.</span></div><div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company’s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While the Company has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company’s continuity plans will be successful. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has already experienced disruptions to its business such as work-from-home orders for offices and similar disruptions have occurred for its partners. Specifically, the outbreak has caused disruptions in its ability to manufacture clinical trial materials, including the acquisition of raw materials needed for such manufacturing, enrollment and treatment of patients in clinical trials in process, and slowdowns and shutdowns of the laboratories and other service providers that are being relied upon in the development of the Company’s product candidates. </span></div>The extent to which the COVID-19 pandemic or any other health epidemic may impact the Company’s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to mitigate its impact, among others. Accordingly, the COVID-19 pandemic could have a material adverse effect on the Company’s business, results of operations and financial condition.
CY2020Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	6.85
CY2020Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	213500000	USD
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	20300253	shares
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72100000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	335400000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates.
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and short-term investments. The Company maintains its cash and cash equivalents at one accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) (see Note 8). </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a single third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div>The Company is highly dependent on two contract research organizations (“CROs”) and a limited number of third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2753774000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9134426000	shares
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	177614000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-63000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	177551000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	32020000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	54000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	32074000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P0Y7M6D
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4480000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3299000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1480000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	862000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2437000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2020Q4	sttk	Accrued Research And Development Contract Costs Current AccruedResearchAndDevelopmentContractCostsCurrent	5382000	USD
CY2019Q4	sttk	Accrued Research And Development Contract Costs Current AccruedResearchAndDevelopmentContractCostsCurrent	2648000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1551000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	966000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	419000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	425000	USD
CY2020Q4	sttk	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	7352000	USD
CY2019Q4	sttk	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	4039000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	585000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	730000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	753000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	775000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	798000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2542000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6183000	USD
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2020Q4	sttk	License Agreement Royalty Payments Maximum LicenseAgreementRoyaltyPaymentsMaximum	20600000	USD
CY2020Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1266000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	461000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1615375	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.60
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M12D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1344058	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	49700000	USD
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.34
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	181449	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.25
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35962	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.94
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2742022	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.95
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M25D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2689012	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.95
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M25D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	868777	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.01
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.93
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.87
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	12400000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5291000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42900000	USD
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	42900000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7687000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5036000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8717000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2948000	USD
CY2020	sttk	Effective Income Tax Rate Reconciliation Return To Provision Adjustment EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment	-745000	USD
CY2019	sttk	Effective Income Tax Rate Reconciliation Return To Provision Adjustment EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustment	-24000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1114000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	672000	USD
CY2020	sttk	Effective Income Tax Rate Reconciliation Other Permanent Differences Amount EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount	119000	USD
CY2019	sttk	Effective Income Tax Rate Reconciliation Other Permanent Differences Amount EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesAmount	82000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	223000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	359000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	487000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9891000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	121000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1345000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	251000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	182000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	25000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3708000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1919000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2631000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3264000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	27000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17784000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8407000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17285000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8233000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	499000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	174000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	158000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	378000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	16000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	499000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	174000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8700000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	560000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	201000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	223000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	359000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	783000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	560000	USD

Files In Submission

Name	View Source	Status
0001680367-21-000008-index-headers.html	Edgar Link	pending
0001680367-21-000008-index.html	Edgar Link	pending
0001680367-21-000008.txt	Edgar Link	pending
0001680367-21-000008-xbrl.zip	Edgar Link	pending
a11.jpg	Edgar Link	pending
a12.jpg	Edgar Link	pending
a43-descriptionofsecurities.htm	Edgar Link	pending
ab1.jpg	Edgar Link	pending
amendment1toandrewneillemp.htm	Edgar Link	pending
amendment1tocasideyoungemp.htm	Edgar Link	pending
amendment1toerinthomsonemp.htm	Edgar Link	pending
amendment1tolinipanditeemp.htm	Edgar Link	pending
amendment2totaylorschreibe.htm	Edgar Link	pending
casideyoungemploymentagree.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
officeleaseagreement-shatt.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sttk-20201231.htm	Edgar Link	pending
sttk-20201231.xsd	Edgar Link	pending
sttk-20201231_cal.xml	Edgar Link	unprocessable
sttk-20201231_def.xml	Edgar Link	unprocessable
sttk-20201231_g1.jpg	Edgar Link	pending
sttk-20201231_g10.jpg	Edgar Link	pending
sttk-20201231_g11.jpg	Edgar Link	pending
sttk-20201231_g12.jpg	Edgar Link	pending
sttk-20201231_g13.jpg	Edgar Link	pending
sttk-20201231_g14.jpg	Edgar Link	pending
sttk-20201231_g15.jpg	Edgar Link	pending
sttk-20201231_g16.jpg	Edgar Link	pending
sttk-20201231_g17.jpg	Edgar Link	pending
sttk-20201231_g18.jpg	Edgar Link	pending
sttk-20201231_g19.jpg	Edgar Link	pending
sttk-20201231_g2.jpg	Edgar Link	pending
sttk-20201231_g20.jpg	Edgar Link	pending
sttk-20201231_g21.jpg	Edgar Link	pending
sttk-20201231_g22.jpg	Edgar Link	pending
sttk-20201231_g23.jpg	Edgar Link	pending
sttk-20201231_g24.jpg	Edgar Link	pending
sttk-20201231_g3.jpg	Edgar Link	pending
sttk-20201231_g4.jpg	Edgar Link	pending
sttk-20201231_g5.jpg	Edgar Link	pending
sttk-20201231_g6.jpg	Edgar Link	pending
sttk-20201231_g7.jpg	Edgar Link	pending
sttk-20201231_g8.jpg	Edgar Link	pending
sttk-20201231_g9.jpg	Edgar Link	pending
sttk-20201231_htm.xml	Edgar Link	completed
sttk-20201231_lab.xml	Edgar Link	unprocessable
sttk-20201231_pre.xml	Edgar Link	unprocessable
sub-certxsection302xarn202.htm	Edgar Link	pending
sub-certxsection302xceo202.htm	Edgar Link	pending
sub-certxsection906ofthesa.htm	Edgar Link	pending
ye2020consent.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STTK
Shattuck Labs Inc Stock $sttk

2019 Q4 Form 10-K Financial Statement

#000168036721000008 Filed on March 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STTK Shattuck Labs Inc Stock $sttk

2019 Q4 Form 10-K Financial Statement

#000168036721000008 Filed on March 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STTK
Shattuck Labs Inc Stock $sttk